The critical consequences of human cytomegalovirus (HCMV) infection in the transplant population and in congenitally infected infants, the limited treatment options for HCMV, and the emergence of resistant mutants during existing therapy fueled the search for new anti-HCMV agents. A pp28-luciferase recombinant HCMV was used as a reporter system for high-throughput screening of HCMV inhibitors. Approximately 400,000 compounds from existing libraries were screened. Subsequent validation assays using resynthesized compounds, several virus strains and detailed virology assays resulted in the identification of five structurally unique and selective HCMV inhibitors, active at sub to low µM concentrations. Further characterization revealed that each compound inhibited a specific stage of HCMV replication. Only one compound was also active against herpes simplex virus. Drug combination studies revealed that all five compounds were additive with ganciclovir or letermovir. Future studies will determine the potential for development of these new compounds as anti-HCMV drugs and their use as probes to study virus-host interaction.
Sicca Symptoms in Parkinson’s Disease: Association with Other Nonmotor Symptoms and Health-Related Quality of Life.
February 28, 2020
Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications.
May 26, 2020
July 18, 2016
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- CROI 2020Every year, CROI hosts some of the world's leading experts in HIV research, who come to present exciting new data and drive forward the field of HIV/AIDS research. This year, due to COVID-19, CROI held their meeting virtually.